ImmuPharma (LON:IMM) Trading Up 9.3% – Should You Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price shot up 9.3% during mid-day trading on Friday . The company traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). 31,272,668 shares changed hands during mid-day trading, an increase of 59% from the average session volume of 19,666,383 shares. The stock had previously closed at GBX 3.60 ($0.04).

ImmuPharma Stock Performance

The firm has a market capitalization of £16.39 million, a PE ratio of -393.60 and a beta of 1.53. The company has a fifty day moving average price of GBX 1.71 and a 200-day moving average price of GBX 1.72.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.